FMS Fresenius Medical Care AG Loading...

From DGX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jul 23 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q2 FY26 call
Quest's partnership with Fresenius is driving volume and expanding its kidney testing portfolio, contributing to revenue growth.
FMS
HIGH
08:30
Apr 21 ◎
Sam Samad Chief Financial Officer, Quest Diagnostics Incorporated DGX Q1 FY26 call
Quest provides lab testing for Fresenius dialysis clinics; this relationship contributes significantly to volume but has a dilutive effect on revenue per requisition.
FMS
HIGH
08:30
Feb 10 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q4 FY25 call
Quest has scaled operations for Fresenius, indicating strong demand for dialysis testing services; Fresenius benefits from Quest's expanded capacity and water purity testing.
FMS
HIGH
08:30
Oct 21 ◎
Jim Davis President and CEO, Quest Diagnostics Incorporated DGX Q3 FY25 call
Quest has won a large enterprise agreement to serve Fresenius dialysis centers, adding revenue and utilizing excess capacity.
FMS
HIGH

About FMS Analyst Coverage

Buzzberg tracks FMS (Fresenius Medical Care AG) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: Jim Davis, Sam Samad.